Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 2/20 | 0.37 |
| ▸ | NEK2 | P51955 | 2/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.37 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.37 |
| ▸ | AGXT | P21549 | 1/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | CDK4 | P11802 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | AKT1 | P31749 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.37 |
| ▸ | DHODH | Q02127 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | BCL2 | P10415 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1386510 | 0.94 | AURKA (0.39) | AURKANEK2TGFBR1MAP4K4PDE10A | |
| SCHEMBL1386167 | 0.93 | PTGS2 (0.43) | MGLLPTGS2AURKANEK2PDE10A | |
| SCHEMBL6531724 | 0.88 | PTGS2 (0.43) | MGLLPTGS2MRGPRX4AGXTCDK2 | |
| SCHEMBL1385049 | 0.86 | PDE10A (0.43) | AURKANEK2PDE10AHTR7LSS | |
| Hydrochloric Acid SCHEMBL2577843 | 0.85 | PDE10A (0.42) | AURKANEK2PDE10AHTR7LSS | |
| SCHEMBL1386325 | 0.85 | GABRG2 (0.42) | AURKANEK2PDE10AHTR7KMT2A | |
| SCHEMBL2584626 | 0.85 | MAOB (0.40) | AURKANEK2ABL1PDE10AHTR7 | |
| SCHEMBL1387082 | 0.81 | PDE10A (0.41) | AURKANEK2PDE10ALSSKMT2A | |
| SCHEMBL1384547 | 0.81 | PDE10A (0.42) | PDE10AHTR7LSS | |
| SCHEMBL1387118 | 0.80 | CNR2 (0.44) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4833078-B2 | — | — | 2011-12-07 | — | — | JP | claimed |
| US-20090170833-A1 | PYRAZOLYL DERIVATIVES, PREPARATION PROCESS AND INTERMEDIATES OF THIS PROCESS AS MEDICINAL PRODUCTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AVENTIS PHARMA S.A. (FR) | 2009-07-02 | — | — | US | claimed |
| WO-2005051917-A9 | PYRAZOLYL DERIVATIVES IN THE FORM OF DRUGS FOR TREATING ACUTE OR CHRONIC NEURONAL REGRESSIONS | AVENTIS PHARMA SA (FR) | 2005-09-29 | — | — | WO | claimed |
| US-20050165005-A1 | Pyrazolyl derivatives, preparation process and intermediates of this process as medicinal products and pharmaceutical compositions containing them | AVENTIS PHARMA S.A. (FR) | 2005-07-28 | — | — | US | claimed |
| US-8048893-B2 | Pyrazolyl derivatives, preparation process and intermediates of this process as medicinal products and pharmaceutical compositions containing them | AVENTIS PHARMA SA (FR) | 2011-11-01 | — | — | US | disclosed |
| US-20090170833-A1 | PYRAZOLYL DERIVATIVES, PREPARATION PROCESS AND INTERMEDIATES OF THIS PROCESS AS MEDICINAL PRODUCTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AVENTIS PHARMA S.A. (FR) | 2009-07-02 | — | — | US | disclosed |
| US-7524838-B2 | Pyrazolyl derivatives, preparation process and intermediates of this process as medicinal products and pharmaceutical compositions containing them | AVENTIS PHARMA S.A. (FR) | 2009-04-28 | — | — | US | disclosed |
| EP-1689720-B1 | PYRAZOLYL DERIVATIVES IN THE FORM OF DRUGS FOR TREATING ACUTE OR CHRONIC NEURONAL REGRESSIONS | AVENTIS PHARMA SA (FR) | 2009-04-15 | — | — | EP | disclosed |
| EP-1689720-A1 | PYRAZOLYL DERIVATIVES IN THE FORM OF DRUGS FOR TREATING ACUTE OR CHRONIC NEURONAL REGRESSIONS | Aventis Pharma S.A. (FR) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005051917-A9 | PYRAZOLYL DERIVATIVES IN THE FORM OF DRUGS FOR TREATING ACUTE OR CHRONIC NEURONAL REGRESSIONS | AVENTIS PHARMA SA (FR) | 2005-09-29 | — | — | WO | disclosed |
| US-20050165005-A1 | Pyrazolyl derivatives, preparation process and intermediates of this process as medicinal products and pharmaceutical compositions containing them | AVENTIS PHARMA S.A. (FR) | 2005-07-28 | — | — | US | disclosed |
| WO-2005051917-A1 | PYRAZOLYL DERIVATIVES IN THE FORM OF DRUGS FOR TREATING ACUTE OR CHRONIC NEURONAL REGRESSIONS | AVENTIS PHARMA S.A. (FR) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170833-A1 | PYRAZOLYL DERIVATIVES, PREPARATION PROCESS AND INTERMEDIATES OF THIS PROCESS AS MEDICINAL PRODUCTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | C1R, CBR3, C3AR1 | MGLL 4860/4885PTGS2 3870/4885AURKA 839/4885 |
| US-20050165005-A1 | Pyrazolyl derivatives, preparation process and intermediates of this process as medicinal products and pharmaceutical compositions containing them | C1R, CBR3, C3AR1 | MGLL 4854/4885PTGS2 3848/4885AURKA 909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.